NEWS

2023

testimonies

A happy customer

Ipratech was proud to deliver a Cytosys machine to Somatek in early 2022. A few months later, the really positive feedback of Somatek is just heartwarming ! Read it below, and find it on our and Somatek’s LinkedIn page.

Come and meet us

Ipratech will be present at the Bioprocess International Europe in Amsterdam, 9-12 May. Let’s met at the booth #143 !

BIE AMS
bioprocessing bcn

Come and meet us

Ipratech will be present at the next Bioprocessing summit Europe in Barcelona, 13-16 March. Don’t forget to visit us at the booth #19 !

2020

IPRATECH CYTOSYS Picture

Great week starting again for IPRATECH!

July

This bioreactor controller update is our latest delivery for biopharma manufacturing.

We are proud of this single-use 50L bioreactor rewamping job. We have installed our CYTOSYS cell culture control mother board with embedded software inside the existing housing, and connected all existing sensors and actuators. The vessel is now ready for plasmid DNA production at Delphi Genetics, Gosselies, Belgium.

Watch this cool technology ! ACOUSTIC FILTRATION

June

The green color of micro-algae allows nice visualization of this filtration technique. CYTOPERF device is originally designed for gentle filtration of mammalian cell in a continuous cell culture perfusion process, however this time we have tested it on micro-algae, and it works great!

3 CYTOPERF IPRATECH

Cell Culture controller installation last week !

May

Last week we have delivered and installed another set of 3 CYTOSYS to control the specific cell culture process of our client.
These news devices have joined the over 20 units sold to this happy customer in the last 3 years.
When it comes to advanced cell culture and perfusion control Ipratech is your partner!

2019

iconsensus

iConsensus

April
Project: high-throughput plateform for development and production
of biopharmaceuticals and vaccines.

IPRATECH is proud to announce his participation in the international iConsensus consortium supported Innovative Medicines Initiative (IMI).